FCMV
CGEM icon

Foresite Capital Management VI’s Cullinan Oncology CGEM Stock Holding History

Foresite Capital Management VI’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-594,025
Closed -$4.47M – 14
2025
Q2 		$4.47M Sell
594,025
-40,533
-6% -$326K 2.51% 13
2025
Q1 		$4.8M Hold
634,558
– – 2.63% 11
2024
Q4 		$7.73M Buy
+634,558
New +$9.12M 3.44% 10

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Foresite Capital Management VI's CGEM Position: Q3 2025 in Review

Foresite Capital Management VI sold out of Cullinan Oncology (CGEM) in Q3 2025, closing a stake of 594,025 shares — an estimated $4.47M sold.

Foresite Capital Management VI first reported a position in CGEM in Q4 2024 and held it in 3 quarters. The position peaked at $7.73M in Q4 2024. 145 funds tracked by Wall St. Rank hold CGEM as of Q3 2025.

  • Foresite Capital Management VI reported no remaining Cullinan Oncology position as of Q3 2025 after selling out during the quarter.
  • Foresite Capital Management VI sold 594,025 Cullinan Oncology shares in Q3 2025, an estimated $4.47M.
  • Foresite Capital Management VI first reported a position in Cullinan Oncology in Q4 2024 and held it in 3 quarters.
  • Foresite Capital Management VI's Cullinan Oncology position peaked at $7.73M in Q4 2024.
  • 145 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2025.

Based on Foresite Capital Management VI's 13F filing for Q3 2025, filed 14 Nov 2025.